Roche Holding AG
RO
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Stocks News & Analysis
stocks
6 undervalued stocks with low beta
Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.
stocks
An undervalued, wide-moat name in healthcare
Companies racing for a coronavirus cure have moved to lofty valuations. Morningstar analyst Alex Morozov is looking for lesser-known healthcare names.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,985.30 | 147.80 | -1.82% |
| CAC 40 | 7,858.83 | 17.53 | -0.22% |
| DAX 40 | 22,390.84 | 149.14 | -0.66% |
| Dow JONES (US) | 42,225.32 | 235.36 | 0.56% |
| FTSE 100 | 8,608.48 | 26.32 | -0.30% |
| HKSE | 23,202.53 | 4.31 | -0.02% |
| NASDAQ | 17,601.05 | 151.16 | 0.87% |
| Nikkei 225 | 34,443.86 | 1,282.01 | -3.59% |
| NZX 50 Index | 12,190.91 | 129.28 | -1.05% |
| S&P 500 | 5,670.97 | 37.90 | 0.67% |
| S&P/ASX 200 | 7,790.40 | 144.10 | -1.82% |
| SSE Composite Index | 3,350.13 | 1.69 | 0.05% |